Core Insights - Progyny's CEO, Pete Anevski, discussed utilization trends and forecasting during a fireside chat, emphasizing the importance of actual benefit use over eligibility counts [4][2] - The company is launching a new fully insured product, Progyny Select, aimed at small group employers, with expectations to go live in 2027 [6][12] Utilization Trends - Anevski highlighted that utilization rates have remained stable historically, ranging from approximately 1.03% to 1.09%, and emphasized that the company focuses on actual benefit usage rather than fluctuating eligibility counts [2][7] - The first quarter typically sees the highest proportion of individuals beginning their fertility journey, with treatment activity often occurring in subsequent quarters [5][1] Forecasting Methodology - Progyny utilizes client history, industry patterns, and member journey signals to predict utilization, with Q1 consultations leading to higher-revenue treatments in Q2 through Q4 [5][8] - The company acknowledges that 2024 may present unique challenges, including a mid-year dip in utilization influenced by the political environment [10] Progyny Select Rollout - The fully insured small-group product will be marketed through brokers and PEOs, with a focus on signing distributors and training brokers ahead of the critical fourth-quarter renewal season [11][12] - The product is designed with risk management features, including IVF-only coverage and lifetime caps, to control utilization risk [6][14] Competitive Landscape - Anevski noted that the recent selling season did not feel more competitive than previous years, with Progyny continuing to win the majority of contracts against competitors [19] - Some competitors have faced challenges, including bankruptcy, which has created opportunities for Progyny to strengthen its market position [19] Technology Investments - Progyny is investing in AI and data technology to enhance services for stakeholders, aiming to reduce friction for patients and improve operational efficiency [17][18] - The company believes that technology can support provider partnerships and potentially lower costs, thereby enhancing its negotiating position [18]

Summary of Progyny Conference Call Company Overview - **Company**: Progyny - **Industry**: Fertility and IVF Benefits - **Position**: One of the largest publicly traded fertility IVF benefit partners Key Points and Arguments Financial Performance - **Fourth Quarter Earnings**: Noted a reduction of 400,000 eligible lives due to administrative corrections from employer clients [1][2] - **Utilization Rate**: Maintained a tight range of 1.03 to 1.09 over the years, focusing on actual utilization rather than just eligible lives [3][4] - **Attrition**: Primarily from lower-utilizing clients, while new sign-ons from the selling season are expected to be better utilizers [5][6] Utilization Trends - **Utilization Timing**: New cohorts typically start utilizing benefits in Q2 through Q4 after initial consultations in Q1 [16][17] - **Consultation to Treatment Cycle**: Average of 1.8 retrievals per live birth, indicating multiple cycles may occur before a transfer [17][18] Progyny Select Program - **Launch Strategy**: The fully insured program is set to go live in 2027, with current efforts focused on signing up distributors and training brokers [23][29] - **Sales Model**: Commission-based structure minimizes upfront expenses, with revenue tied to client renewals [30][32] - **Risk Mitigation**: Designed to address small group employers, with underwriting based on extensive data from smaller clients [35][37] Market Opportunities and Challenges - **State Mandates**: California's IVF mandate could significantly increase volumes, but competition remains a challenge [48][50] - **Education and Awareness**: Emphasis on educating brokers and distribution partners about the benefits of Progyny's offerings [51][52] Competitive Landscape - **Market Position**: Despite competition, Progyny continues to win the majority of clients, with some competitors facing financial challenges [80][81] - **Investment in Offerings**: Ongoing investments to enhance services and maintain a competitive edge [81] Technology and Data Utilization - **AI and Data Integration**: Investments in technology aim to improve client experiences and outcomes by automating tasks and providing better recommendations [75][78] Progyny Rx - **Patient Assistance Program**: Progyny Rx is not designed for those with coverage, focusing instead on those without insurance [60][62][70] - **Impact on Business**: No expected impact on Progyny's business from the Progyny Rx program as it serves a different market segment [73] Additional Important Insights - **Retention Rates**: High retention rates (99%) attributed to comprehensive program management for clients [42] - **Market Dynamics**: The competitive environment remains stable, with no significant increase in competition noted [81] This summary encapsulates the key discussions and insights from the conference call, highlighting Progyny's strategic focus, market positioning, and operational dynamics.

Summary of Progyny (NasdaqGS:PGNY) 2026 Conference Call Company Overview - **Company**: Progyny, a healthcare technology company specializing in fertility benefits and services Key Points Industry Dynamics - **Healthcare Sector Growth**: Progyny has seen a significant increase in healthcare clients, now representing the largest percentage of their industry exposure, driven by the need for fertility support among large hospital systems and healthcare providers [38][44] - **Fertility Support Demand**: The company emphasizes the importance of fertility benefits, especially in industries with a large female workforce, which has led to a competitive advantage in attracting healthcare clients [44][45] Financial Performance - **2025 Utilization Trends**: The company reported improving utilization rates in 2025, with consistent consumption patterns observed throughout the year. Utilization is defined as the number of members engaging with the services [5][6][10] - **Revenue Model**: Progyny operates on a consumption model rather than a per-member-per-month model, meaning revenue is driven by actual service usage rather than membership counts [12][16][24] Membership and Client Dynamics - **Membership Adjustments**: The company has experienced variability in membership counts, which has not negatively impacted revenue due to the nature of their consumption model. They maintain a hands-off approach in addressing discrepancies in client-reported member counts [12][15][24] - **New Client Acquisition**: Approximately 50% of new clients are adopting fertility benefits for the first time, while the other half are transitioning from traditional carrier benefits [46] Product and Service Innovations - **Smart Cycle Utilization**: The Smart Cycle model allows for flexible treatment options, and clients are increasingly opting for more comprehensive coverage, including unlimited Smart Cycles [49] - **New Product Launches**: Progyny has introduced menopause and pregnancy/postpartum products, which have seen positive adoption rates. The company is focused on increasing awareness and utilization of these services [63][64] Technology and AI Integration - **IT Investments**: Progyny is investing in IT systems to enhance member engagement and improve service delivery. The focus is on maintaining a human touch in patient care while leveraging AI for operational efficiencies [51][52][53] - **AI's Role**: The company views AI as a tool for improving business operations rather than replacing human roles, particularly in patient care advocacy [51][53] Future Outlook - **Progyny Select Launch**: The new Progyny Select product aims to provide fertility benefits to smaller companies, with positive feedback from initial market testing. The company is cautious about setting expectations for its first year [72][74] - **Risk Management**: The company has designed the Progyny Select product to mitigate risks associated with underwriting, including fixed Smart Cycle limits and a risk premium in pricing [78][82] Financial Strategy - **Share Buyback Program**: Progyny is actively engaged in a share buyback program, with a focus on returning capital to shareholders while managing growth and operational needs [91][92] Additional Insights - **Pharmacy Management**: The company emphasizes the importance of managing drug costs and usage effectively, highlighting the potential for significant savings through their holistic approach to fertility services [87][88] This summary encapsulates the key insights and strategic directions discussed during the Progyny conference call, reflecting the company's focus on growth, innovation, and client satisfaction in the fertility benefits sector.

Financial Data and Key Metrics Changes - Progyny reported record highs in revenue and adjusted EBITDA for 2025, with revenue reaching $1.29 billion and adjusted EBITDA at $222 million, both metrics increasing double digits over 2024 [7][8] - Operating cash flow for 2025 was a record $210 million, an increase of 17% over 2024 [7][23] - The company achieved a nearly 200 basis point expansion in full-year gross margin versus 2024, reflecting efficiencies in care management and service delivery [21] Business Line Data and Key Metrics Changes - The company maintained nearly 100% client retention, with 30% of its client base expanding their benefits for 2026 through upsells and service enhancements [9][11] - Member engagement and utilization rates remained healthy, with overall member activity exceeding guidance assumptions [20] Market Data and Key Metrics Changes - The self-insured market is expected to continue comprising the majority of new lives added, with opportunities to broaden the target market to smaller employers [12][13] - The healthcare industry has proven resilient to macro uncertainties, contributing to the company's growth momentum entering 2026 [12] Company Strategy and Development Direction - Progyny is focusing on expanding its services to smaller employers through Progyny Select, which aims to provide a fixed premium product that minimizes financial risk for these employers [14][16] - The company plans to leverage its operational infrastructure for efficient distribution through brokers and third-party partners [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for family building and women's health services, noting strong early results in the selling season for 2026 [12][13] - The company anticipates 7.2 million covered lives in 2026, a reduction from previous estimates due to administrative updates from existing clients [26][27] Other Important Information - The company reported a significant increase in capital expenditures, with fourth quarter CapEx at approximately $5.5 million, reflecting a $3.5 million increase over the prior year [23] - Stock-based compensation expense is expected to decrease by approximately 35% in 2026, contributing to improved profitability [31] Q&A Session Summary Question: Clarification on membership outlook for 2026 - Management clarified that the changes in membership figures relate to existing clients and are primarily administrative updates, not indicative of workforce reductions [36][37] Question: Concerns about Progyny Rx model and economics - Management stated there has been no pushback from employers regarding the Progyny Rx model, which includes rebates at the point of sale [39][40] Question: Strategy and pricing for Progyny Select - Management explained that the pricing for Progyny Select is based on underwriting experience from smaller clients, with guardrails in place to manage risk [44][46] Question: Contribution from maternal health services - Management indicated that while maternal health services are growing, they are not yet material to overall revenue [58][59] Question: Expectations for CapEx in 2026 - Management anticipates a step-up in CapEx for 2026, but not a doubling compared to 2025 [90] Question: Changes in conversations with clients regarding the labor market - Management noted that conversations with clients have not changed significantly, and the current pipeline remains strong [100][102]

Financial Data and Key Metrics Changes - Progyny reported record highs in revenue and adjusted EBITDA for 2025, with revenue reaching $1.29 billion and adjusted EBITDA at $222 million, both metrics increasing double digits over 2024 [7][8] - Operating cash flow for 2025 was a record $210 million, an increase of 17% over 2024 [7] - The company achieved a nearly 200 basis point expansion in full-year gross margin versus 2024, reflecting efficiencies in care management and service delivery [21] Business Line Data and Key Metrics Changes - The company maintained nearly 100% client retention, with 30% of its client base expanding their benefits for 2026 through upsells and service enhancements [9][11] - Member engagement and utilization rates remained healthy, with overall member activity exceeding guidance expectations [20] Market Data and Key Metrics Changes - The self-insured market is expected to continue comprising the majority of new lives added, with opportunities to target smaller employers who have not previously had access to Progyny's benefits [13][14] - The healthcare industry has proven resilient to macro uncertainties, contributing to the company's growth momentum entering 2026 [12] Company Strategy and Development Direction - Progyny is focusing on expanding its target market by introducing Progyny Select, a solution aimed at smaller employers, which is expected to launch in 2026 [14][16] - The company plans to leverage its operational infrastructure for efficient distribution through brokers and third-party partners [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's performance and growth potential, citing strong demand for family building and women's health services [12][17] - The company anticipates 7.2 million covered lives in 2026, reflecting a net reduction due to administrative updates rather than workforce reductions [26][27] Other Important Information - The company repurchased over 3.3 million shares for nearly $84 million under its share repurchase program [25] - A significant reduction in stock-based compensation expense is expected in 2026, down approximately 35% from 2025 [31] Q&A Session Summary Question: Clarification on membership outlook for 2026 - Management clarified that the changes in membership figures relate to existing clients and are due to administrative updates rather than new client issues [36][37] Question: Discussion on Progyny Rx model and economics - Management noted no pushback from employers regarding the Progyny Rx model, emphasizing the value delivered through integrated programs [39][40] Question: Strategy and pricing for Progyny Select - Management explained that pricing for Progyny Select is based on experience data from smaller clients, with risk guardrails in place to manage variability [44][46] Question: Contribution from maternal health services - Management indicated that while maternal health services are growing, they are not yet material to overall financials [57][58] Question: Insights on administrative changes in membership - Management stated that administrative changes were observed across various industries, with no significant impact on overall utilization rates [100][104]

Financial Data and Key Metrics Changes - Progyny reported record highs in revenue and adjusted EBITDA for 2025, with revenue reaching $1.29 billion and adjusted EBITDA at $222 million, representing increases of nearly $90 million and $28 million respectively over the midpoint of original guidance [6][19] - Operating cash flow for 2025 was a record $210 million, an increase of 17% compared to 2024 [6][21] - The company achieved a nearly 200 basis point expansion in full-year gross margin versus 2024, reflecting efficiencies in care management and service delivery [19] Business Line Data and Key Metrics Changes - Member engagement remained healthy, with utilization and consumption of ART cycles per unique utilizer pacing favorably against guidance [18] - 30% of the client base expanded their benefits with Progyny for 2026 through upsells and service enhancements, providing access to new services for over 2.7 million members [10] Market Data and Key Metrics Changes - The self-insured market is expected to continue comprising the majority of new lives added, with opportunities to broaden the target market to smaller employers [12] - The healthcare industry, as the largest sector for Progyny, has shown resilience against macro uncertainties over the past five years [11] Company Strategy and Development Direction - Progyny is focusing on member and client satisfaction, which has led to nearly 100% client retention, including all largest employers [7] - The company is launching Progyny Select to address the needs of smaller employers, providing a fixed premium product that minimizes financial risk [13][14] - Investments in technology, including AI, are aimed at enhancing member experience and driving efficiencies [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 with considerable momentum, driven by strong demand for family building and women's health services [11] - The guidance for 2026 anticipates 7.2 million covered lives, reflecting a net reduction due to administrative updates rather than workforce reductions [23] - The company expects revenue growth of 5.1% to 9% for 2026, with adjusted EBITDA projected between $224 million and $239 million [29][30] Other Important Information - The departure of the President at the end of 2025 resulted in an incremental $7.7 million in stock-based compensation expense [25] - The company repurchased over 3.3 million shares for nearly $84 million under its share repurchase program [22] Q&A Session Summary Question: Clarification on membership outlook for 2026 - Management clarified that the changes in membership figures relate to existing clients and are due to administrative updates rather than new client issues [33][34] Question: Discussion on Progyny Rx model and economics - Management noted no pushback from employers regarding the Progyny Rx model and emphasized the value delivered through integrated programs [36][37] Question: Strategy and pricing for Progyny Select - Management explained that pricing for Progyny Select is based on experience data from smaller clients, with guardrails in place to manage risk [41][44] Question: Contribution from maternal health services - Management indicated that while maternal health services are growing, they are not yet material but serve as a value add [55] Question: Expectations for CapEx and cash flow conversion - Management anticipates a step-up in CapEx for 2026 but not a doubling, with a cash flow conversion rate of approximately 75% from adjusted EBITDA [82][84]

Summary of Progyny Conference Call Company Overview - **Company**: Progyny - **Industry**: Healthcare Facilities, specifically women's health and family-building benefits - **Key Executives Present**: CEO Pete Anevski, CFO Mark Livingston, Chief Commercial Officer Katie Higgins, COO Melissa Cummings [1][2] Core Business and Services - Progyny provides comprehensive benefits related to women's health and family-building, including fertility, adoption, surrogacy, pregnancy, postpartum, and menopause [3][4] - The company emphasizes expert care and support for members, leading to significant revenue growth and profitability since its IPO in 2019 [4] Market Insights and Trends - The prevalence of infertility is reported as 1 in 5, highlighting a significant need for related benefits [5] - Employers are increasingly focused on providing benefits that meet employee needs while managing medical costs [5][6] - Progyny has demonstrated a 5% compounded increase in medical costs over three years, compared to 27% for the broader market, indicating effective cost management [6][7] Client Retention and Growth - Progyny added 900,000 lives in the 2025 selling season with nearly 100% client retention [8][12] - Clients are not only retaining benefits but also expanding them, with 30% of the book of business adding to their benefits [12] Diversification and Risk Management - The company has reduced its exposure to the tech industry, with the largest industry now representing only 15% of lives covered, down from 18% [17][18] - The largest client is projected to represent only a mid-single-digit percentage of revenue in 2026, mitigating individual client risk [18] New Product Launch: Progyny Select - Progyny Select is designed for small employers (100+ employees) and offers a fully insured, pooled risk model for infertility benefits [19][21] - This market represents an additional 50 million covered lives, expanding Progyny's addressable market significantly [20][24] New Services and Offerings - Recent service expansions include pregnancy, postpartum, parenting, leave and benefit navigation, and menopause, aimed at enhancing member experience [25][26] - The company is focused on integrating these services to provide a cohesive experience for members [26] Global Expansion - Progyny's acquisition of Apryl in 2024 allows for a unified global offering that addresses women's health and family-building services across different countries [28][29] - The focus is on providing local customization while maintaining global consistency [30] Financial Performance and Cash Flow - Progyny has maintained a strong conversion rate of Adjusted EBITDA to cash flow, exceeding a 75% target [31] - The company plans to continue investing in business expansion, including new offerings and go-to-market resources [32] Future Outlook - The leadership expresses confidence in the growth potential of Progyny Select and the overall business strategy for 2026 and beyond [34][61] - The company aims to demonstrate its ability to grow sustainably despite macroeconomic challenges [63] Competitive Landscape - Progyny positions itself as a leader in the market, contrasting with competitors who may struggle with cash flow and business models [51][52] - The company welcomes competition, believing the market is large enough for multiple players [52] Conclusion - Progyny is well-positioned for future growth with a diversified client base, new product offerings, and a strong focus on member experience and cost management [64]

JP Morgan Presentation January 2026 1 Today's Speakers 2 Pete Anevski Chief Executive Officer Melissa Cummings Chief Operating Officer Katie Higgins Chief Commercial Officer Mark Livingston Chief Financial Officer Safe Harbor Statement Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements co ...